Product Reports Resources Pricing Login Book a demo
COMPANY PROFILE

ACEA Biosciences

Request full access

Evelopment and commercialization of high performance cell analysis platforms for life science research

San Diego, United StatesFounded 2002Biotech & Life Sciences

About ACEA Biosciences

ACEA Biosciences Inc., founded in 2002 by Lin Jixun and Feng Lin, operates as a developer of cell analysis instruments for the life science research market. The company established its headquarters in San Diego, California, with significant manufacturing and R&D operations located in Hangzhou, China. A major milestone in the company's history was the acquisition by Agilent Technologies in September 2018 for $250 million in cash, a strategic move for Agilent to expand its footprint in the cell analysis sector.

The company's business model revolves around the development, manufacturing, and sale of advanced cell analysis platforms to academia, as well as the biotech and pharmaceutical industries. These instruments are utilized in a wide range of applications, including preclinical drug discovery and development, toxicology, and safety pharmacology. ACEA Biosciences generates revenue through the sale of its instrument systems, associated software, and consumables. Before its acquisition, the company had successfully raised $37.9 million in funding over two rounds to support its growth and product development.

ACEA is recognized for two main product lines: the xCELLigence Real-Time Cell Analysis (RTCA) systems and the NovoCyte benchtop flow cytometers. The xCELLigence platform utilizes non-invasive microelectrodes in multiwell plates to monitor cellular behavior like growth, function, and responses to treatments in real-time, without the need for labels. This provides researchers with information-rich data from various cell-based assays. The NovoCyte portfolio offers high-performance, customizable flow cytometers that enable multi-parameter cellular analysis, capable of detecting up to fifteen parameters. These systems are designed to be intuitive, with automated maintenance functions and flexible configurations to meet diverse research needs.

Source: Dealroom company data

At a glance

Status
Acquired
Founded
2002
Headquarters
San Diego, United States
Employees
54
Open positions
None listed
Dealroom signal
64.5/100
Industry
Health
Sub-industry
BioTechnology
Sector
Biotech & Life Sciences, Analytics, Biotechnology, Biotech and Pharma, Hard Tech, DT and LS, science-based
Business model
Manufacturing
Client focus
B2B

Funding history

5 recorded events

Company financing events and reported valuations.

Deal typeDateAmountValuationInvestorsSource
LATE VCOther financing Mar 2019 $20M $80M Qiming Venture Partners —
ACQUISITIONOther financing Sep 2018 $250M $250M Agilent —
Showing the latest 2 of 5 recorded eventsBook a demo for the full funding history →

Growth signals

ACEA Biosciences website traffic

Latest recorded traffic for ACEA Biosciences is 380 monthly website visits, up 245.5% over the last three months. ACEA Biosciences's team declined 29.9% over the past year.

Latest monthly visits380 3-month web change+245.5% 1-year team growth-29.9%
Summary metrics are public; monthly history is available with a demoCompare with peers →

Investments and acquisitions

Capital deployed

Recent portfolio relationships for companies that also act as investors or acquirers.

ACEA Biosciences in the San Diego ecosystem

Live from Dealroom

The ACEA Biosciences office with the hot startups, most funded companies and investors around it. Hover or tap a pin.

Loading the map…

Dealroom maps whole ecosystems like this one for cities, regions and governments. See the ecosystem platform →

Investors

3 investors on the cap table

From Dealroom's funding and investor records, grouped by the round each investor first entered.

Series A1 investor entered at this stage

  • Lilly Asia Ventures

Series B and later1 investor entered at this stage

Other known investors1 additional known investor

  • Agilent
Team profiled 3 named & role-tagged
Founders Hidden — book a demo/100 quality score
Key operators Hidden — book a demo quality score
Potential founders Hidden — book a demo likely future founders
Startup mafia Hidden — book a demo alumni-founded startups
Talent movements Hidden — book a demo in · Hidden — book a demo out past 12 months

Source: Dealroom Talent Intelligence.

Global footprint

Workforce and web traffic by country
Workforce by country
5 countries with
team presence
🇺🇸 United States52%
🇨🇳 China32%
🇬🇧 United Kingdom8%
🇫🇷 France4%
🇻🇳 Vietnam4%
5 countries shown

Market sentiment

Posts on X, past 7 days

An AI-synthesised read of the highest-engagement posts about ACEA Biosciences on X, ranked by likes and reposts, corporate channels excluded.

Reading the room on X — pulling top posts and synthesizing themes…

Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour

See ACEA Biosciences’s full profile on Dealroom

Request a free trial to see the complete deal history, financials, people graph and growth signals.

Takes under a minute. Already use Dealroom? Log in.